Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Synonyms: Marchiafava-Micheli anaemia
There are three features of paroxysmal nocturnal haemoglobinuria (PNH) that are most uncommon together and the finding of them all is pathognomonic:
- There is an acquired haemolytic anaemia due to the susceptibility of the erythrocyte membrane to the haemolytic action of complement.
- There are thromboses in large vessels, such as hepatic, abdominal, cerebral and subdermal veins.
- There is deficient haematopoiesis that may be mild or severe and cause a pancytopenia with aplastic anaemia.
Haemoglobin is normally contained within the erythrocytes. It is only in haemolysis that it is free in the circulation, filtered by the glomeruli and present in the urine. It was originally thought that respiratory drive diminished in sleep, causing acidosis, activation of complement and haemolysis in this condition. However, 'paroxysmal' is an incorrect description: haemolysis actually occurs all day but the more concentrated urine at night makes it appear darker and the haemoglobinuria is more obvious. In PNH there is a marked deficiency or absence of the complement regulatory proteins CD55 and CD59.
This is a haematopoietic stem cell mutation defect of the PIGA gene in the X chromosome.
- It is not familial and sex distribution is equal.
- It is rare but may be slightly less rare in Southeast Asian communities.
The affected stem cell clone passes the gene to all its descendants (red cells, white cells and platelets) producing a haematological mosaic. The proportion of erythrocytes derived from this stem cell determines the severity of the disease.
PNH can present anywhere from early childhood to very late in life. In childhood and adolescence the features are more orientated towards the aplastic anaemia.
Presentation is usually along the lines of one of the three aspects of the disease:
- Haemolytic anaemia. This is the most common form of presentation. There is haemoglobinuria that is often mistaken for haematuria. The urine is dark brown in colour, especially the first of the morning.
- Thrombosis. This is usually in veins rather than arteries and tends to affect hepatic, abdominal, cerebral and subdermal veins. The exact presentation will depend upon the veins involved - eg, Budd-Chiari syndrome, abdominal, or cerebral vein thrombosis. A 2015 review found that females with PNH were notably more likely than males to have a cerebral vein thrombosis.Thrombosis of dermal veins can cause raised, painful and red nodules in the skin over large areas, like the entire back. It subsides within a few weeks but occasionally necrosis requires skin grafts.
- Deficient haematopoiesis. This will produce symptoms of anaemia-like shortness of breath on exertion and fatigue. Neutropenia and thrombocytopenia may allow infection and purpura.
Other symptoms are related to smooth muscle dysfunction and include oesophageal spasms that occur in the morning and resolve in the day. Males often have erectile dysfunction.
Physical signs will depend upon the systems involved:
- Anaemia will cause pallor.
- Infections may produce fever and purpura may be apparent.
- The Budd-Chiari syndrome will produce hepatomegaly and ascites. There may be splenomegaly too.
- Ischaemia of the gut produces absent bowel sounds.
- Cerebral vein thrombosis can produce papilloedema and other neurological signs.
- Red, painful nodules may occur in the skin.
- Dipstick urine tests for blood will be positive but microscopy will not show red blood cells. This is the difference between haematuria and haemoglobinuria.
- FBC will show varying degrees of anaemia, usually of a normochromic, normocytic picture, although high cell turnover can produce folate deficiency and a picture of macrocytosis. White cells and platelets may be reduced. The reticulocyte response may be high or low depending upon whether the picture is predominantly one of haemolytic anaemia or aplastic anaemia.
- LDH is elevated with haemolysis and haptoglobin low or absent.
- Bone marrow examination will differentiate an erythroid and hyperplastic marrow during the haemolytic phase or a hypoplastic marrow in the aplastic phase.
- Leukocytes have a low alkaline phosphatase score as in chronic myeloid leukaemia.
- Flow cytometry: blood test to detect CD59 (MIRL), a glycoprotein, and CD55 (DAF) in regulation of complement action. Absence or reduced expression of both CD59 and CD55 on PNH red blood cells is diagnostic.
- MRI with contrast can demonstrate saggital vein thrombosis.
- Venography can show thrombosis of major veins.
- MRI, ultrasound or technetium 99m Tc colloid scan of the liver and spleen may demonstrate hypoperfusion.
The combination of haemolytic anaemia, aplastic anaemia and thrombosis is diagnostic but not all three features may be immediately apparent.
Blood transfusion may be required but leukocyte depletion is necessary to reduce antibody formation aggravating haemolysis. There is a risk of meningococcal infection and so meningococcal vaccination is essential.
- This is a humanised monoclonal antibody that binds and prevents activation of complement C5 and the subsequent formation of the cytolytic membrane attack complex of complement. It is administered by infusion under expert guidance.
- It reduces intravascular haemolysis and haemoglobinuria, stabilises haemoglobin concentration and reduces the need for transfusion.
- Long-term safety and efficacy of eculizumab have been shown in studies. Survival for those treated with eculizumab was not different from that of a sex-matched and age-matched control group from the general population.
- It has been shown to improve quality of life in patients with PNH[7, 8].
- A 2014 Cochrane review concurred with the findings above but concluded that the use of eculizumab for patients with PNH could neither be supported or rejected and recommended further, high-quality studies.
Although chronic treatment with eculizumab increases the risk of infections with Neisseria meningitides, the drug is generally safe and well tolerated. However, as is the case with other drugs developed for treatment of ultra-orphan diseases, eculizumab is expensive and treatment must continue indefinitely because C5 inhibition does not affect the process that underlies PNH. Moreover, due to the heterogeneous nature of the disease, treatment with eculizumab is not appropriate for all patients with PNH.
- For patients who are not treated with eculizumab, consideration of primary anticoagulation prophylaxis should be given to reduce the risk of thrombosis if there is no contra-indication.
- Management of acute thrombotic events requires immediate full anticoagulation (having excluded significant contra-indications) - beginning with heparin - and starting eculizumab. Subsequent anticoagulation with vitamin K antagonists should be maintained long-term.
- Pregnancy with PNH requires careful management.
- This successfully reduces haemolysis in about 70% of cases.
- The dose for adults is 20-40 mg daily during periods of haemolysis, reduced to that dose on alternate days at other times.
- However, long-term toxicity of corticosteroids significantly limits their attractiveness as a treatment.
Bone marrow transplantation
Allogeneic bone marrow transplantation can cure classic PNH but treatment-related toxicity is a major problem.
This depends upon severity of symptoms and complications. The abnormal clone responsible for the disease may die out but this usually takes at least five years and may take 15-20 years. Acute infection can reactivate the clone.
Thromboembolism is the most common cause of death in patients with PNH: the condition accounts for approximately 40-67% of deaths of which the cause is known.
Did you find this information useful?
Further reading & references
- DeZern AE, Brodsky RA; Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia. Hematol Oncol Clin North Am. 2015 Jun 29(3):479-94. doi: 10.1016/j.hoc.2015.01.005. Epub 2015 Mar 7.
- Phosphatidylinositol Glycan Anchor Biosynthesis Class A Protein, PIGA (Paroxysmal Nocturnal Hemoglobinuria); Online Mendelian Inheritance in Man (OMIM)
- Meppiel E, Crassard I, Peffault de Latour R, et al; Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: a series of 15 cases and review of the literature. Medicine (Baltimore). 2015 Jan 94(1):e362. doi: 10.1097/MD.0000000000000362.
- Bene MC, Le Bris Y, Robillard N, et al; Flow cytometry in hematological nonmalignant disorders. Int J Lab Hematol. 2016 Feb 38(1):5-16. doi: 10.1111/ijlh.12438. Epub 2015 Nov 6.
- Parker C; Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009 Feb 28 373(9665):759-67. Epub 2009 Jan 12.
- Parker CJ; Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol. 2012 May 19(3):141-8. doi: 10.1097/MOH.0b013e328351c348.
- Hillmen P, Young NS, Schubert J, et al; The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21 355(12):1233
- Hillmen P, Hall C, Marsh JC, et al; Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004 Feb 5 350(6):552
- Marti-Carvajal AJ, Anand V, Cardona AF, et al; Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev. 2014 Oct 30 (10):CD010340. doi: 10.1002/14651858.CD010340.pub2.
- Hill A, Kelly RJ, Hillmen P; Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013 Jun 20 121(25):4985-96
- Parker CJ; Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology Am Soc Hematol Educ Program. 2011 2011:21-9. doi: 10.1182/asheducation-2011.1.21.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.